Jennerex/Lee’s Pharma Report Positive Phase II Data for Cancer Drug

Jennerex, a San Francisco clinical-stage biotech focused on cancer therapies, released positive data on its novel treatment for liver cancer, JX-594. Lee’s Pharma of Hong Kong has in-licensed China rights to the drug, and will conduct the China portion of a global Phase III trial. About 600,000 cases of hepatocellular carcinoma are diagnosed each year, of which 350,000 are in China. The US reports only 20,000 new cases every year. More details.... Stock Symbol: (HK: 8221)     Share this with colleagues: